![Vittorio Laurent](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Vittorio Laurent
Direttore/Membro del Consiglio presso ERC-Belgium SA
Profilo
Vittorio Laurent has a current job as a Director at ERC-Belgium SA.
Posizioni attive di Vittorio Laurent
Società | Posizione | Inizio |
---|---|---|
ERC-Belgium SA
![]() ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | Direttore/Membro del Consiglio | 15/06/2019 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
ERC-Belgium SA
![]() ERC-Belgium SA Pharmaceuticals: MajorHealth Technology ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos. | Health Technology |
- Borsa valori
- Insiders
- Vittorio Laurent